Literature DB >> 11579214

Binding of the low density lipoprotein receptor-associated protein (RAP) to thyroglobulin (Tg): putative role of RAP in the Tg secretory pathway.

M Marinò1, L Chiovato, S Lisi, A Pinchera, R T McCluskey.   

Abstract

The 39-44 kDa protein known as the receptor-associated protein binds to members of the low density lipoprotein receptor family and is found within cells that express these receptors. The receptor-associated protein has been shown to prevent premature binding of ligands to the receptors in the endoplasmic reticulum and to promote proper folding and transport of the receptors in the secretory pathway. In the thyroid, megalin (a low-density lipoprotein receptor family member) serves as an endocytic receptor for thyroglobulin. Here we present evidence that the receptor-associated protein can bind to thyroglobulin, which suggests a novel function of the receptor-associated protein, namely binding of certain megalin ligands possibly during the biosynthetic pathway. In solid-phase assays thyroglobulin was shown to bind to the receptor-associated protein with moderately high affinity (mean between K(d) and K(i) = 39.8 nM), in a calcium-dependent and saturable manner. The receptor-associated protein also bound to a native carboxyl-terminal 230-kDa thyroglobulin polypeptide, which markedly reduced binding of intact thyroglobulin to the receptor associated protein, indicating that the receptor-associated protein binding sites of thyroglobulin are located in the carboxyl-terminal portion of the molecule. In addition to thyroglobulin, the receptor-associated protein specifically bound to another megalin ligand, namely lipoprotein lipase. Because lipoprotein lipase markedly reduced receptor-associated protein binding to thyroglobulin, we concluded that the receptor-associated protein uses the same binding site/s to bind to thyroglobulin and lipoprotein lipase. Evidence of thyroglobulin binding to the receptor-associated protein was also obtained in vivo and in cultured thyroid cells. Thus, anti-receptor-associated protein antibodies precipitated intact thyroglobulin from extracts prepared from rat thyroids and cultured thyroid cells (FRTL-5 cells). Chase experiments after inhibition of protein synthesis in FRTL-5 cells showed that thyroglobulin interacts with the receptor-associated protein shortly after the beginning of thyroglobulin biosynthesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11579214     DOI: 10.1210/mend.15.10.0710

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  5 in total

1.  Sequencing of the entire coding region of the receptor associated protein (RAP) in patients with primary hypothyroidism of unknown origin.

Authors:  S Lisi; R Botta; A Pinchera; C Di Cosmo; A Perri; G De Marco; F Menconi; M Marinò
Journal:  J Endocrinol Invest       Date:  2007-11       Impact factor: 4.256

2.  Binding of thyroglobulin (Tg) to the low-density lipoprotein receptor-associated protein (RAP) during the biosynthetic pathway prevents premature Tg interactions with sortilin.

Authors:  R Botta; S Lisi; G Rotondo Dottore; P Vitti; M Marinò
Journal:  J Endocrinol Invest       Date:  2017-04-05       Impact factor: 4.256

3.  Kidney abnormalities in low density lipoprotein receptor associated protein knockout mice.

Authors:  S Lisi; R Botta; A Pinchera; A Bernard Collins; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2008-01       Impact factor: 4.256

4.  Impaired thyroglobulin (Tg) secretion by FRTL-5 cells transfected with soluble receptor associated protein (RAP): evidence for a role of RAP in the Tg biosynthetic pathway.

Authors:  S Lisi; L Chiovato; A Pinchera; C Marcocci; F Menconi; E Morabito; M A Altea; R T McCluskey; M Marinò
Journal:  J Endocrinol Invest       Date:  2003-11       Impact factor: 4.256

5.  Intracellular retention of thyroglobulin in the absence of the low-density lipoprotein receptor-associated protein (RAP) is likely due to premature binding to megalin in the biosynthetic pathway.

Authors:  S Lisi; R Botta; G Rotondo Dottore; M Leo; F Latrofa; P Vitti; M Marinò
Journal:  J Endocrinol Invest       Date:  2016-04-19       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.